Amarin Corp Plc (AMRN)

[rfj1862]

Doing a quick trial is a very sensible idea.

No no no.

1. The #1 rule in drug development is not to take unnecessary risks.
2. The trial would not be small or quick. There is too much interpatient variability to just do 15-20 patients per arm. You'd need much more than that to have confidence in the results.

I don't understand how people who are presumably proponents of this company play so naively into the hands of the naysayers.